高盛-复宏汉霖(2696.HK)业绩回顾:营收稳健且盈利可持续;海外生物类似药迎来拐点:买入-Henlius Biotech(2696.HK):Earnings Review:Solid topline with sustainable profitability;Overseas biosimilar inflection-20260323【6页】

发表回复

后才能评论